In-depth analysis of the appraisal outcomes for all currently-approved gene therapy products allowed for the identification of key clinical and economic challenges across products and geographies
Recommendations developed to help mitigate these challenges are feeding into the clinical development program for the client’s novel gene therapy product
Inbeeo conducted an analysis of all approved gene therapy products to inform the early product development strategy in order to mitigate common payer challenges.
Gene therapies pose a number of unique challenges to payers. Inbeeo’s client needed to develop a detailed understanding of EU5 and US payers’ concerns relating to both clinical and economic evidence, to inform their early stage development program for a novel specialty asset.
HOW WE APPROACHED THE CHALLENGE
An initial review of the landscape across the EU5 and US identified several important opportunities for gene therapies, but also significant market access challenges.
In order to fully understand payers’ specific reactions to gene therapies, a deep-dive review of all approved therapies was conducted, which involved analysis of the clinical evidence base, alongside all published HTA appraisals.
This allowed for the identification of common pitfalls faced by gene therapies, and for an archetyping of the payer landscape according to their engagement.